Aneurysm, BrainPRAEMIUMNCT04819074
Prediction of Outcomes After Surgery for Unruptured Intracranial Aneurysms
An observational study of Aneurysm, Brain, run by University of Zurich at 37 sites in 10 countries.
Trial summary
Accurate preoperative identification of patients at high risk for adverse outcomes would be clinically advantageous, as it would allow enhanced resource preparation, better surgical decision-making, enhanced patient education and informed consent, and potentially even modification of certain modifiable risk factors. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Aneurysm, Brain
- What is being tested?
- Microsurgery
- Type of treatment
- Surgery or procedure
- How many people
- 4,000 participants
- Where
- 37 sitesin 10 countries
- Study dates
- 20 May 2021to 1 Oct 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Adult, Older adult
Study population: We will include all adult patients (18 years or older) undergoing microsurgical treatment for UIAs. No specific exclusion criteria will be set. Patients with prior SAH may only be included when surgical treatment occurred at least 4 weeks after ictus. Only patients treated from January 1st 2010 onwards can be included in this study.
Who may be able to join
- Adult patients (18 or older)
- Undergone microsurgical treatment for unruptured intracranial aneurysm
- Patients with prior SAH may only be included when surgical treatment occurred at least 4 weeks after ictus.
- Treated from January 1st 2010 onwards
Who cannot join
- No specific exclusion criteria
Trial locations and contacts
37 sites in 10 countries.
37 sites in 10 countries
United States10 sites, 10 recruiting
- Not yet recruiting
Emory University Hospital
Atlanta, Georgia, 30322
Daniel Barrow
- Not yet recruiting
Brigham and Women's Hospital
Boston, Massachusetts, 02115
Antonio Chiocca
- Not yet recruiting
University of Illinois
Chicago, Illinois, 60612
Fady Charbel
- Not yet recruiting
UCLA
Los Angeles, California, 90095
Linda Liau
- Not yet recruiting
University of Wisconsin
Madison, Wisconsin, 53792
Mustafa K Baskaya
- Not yet recruiting
North Shore University Hospital
Manhasset, New York, 11030
Amir Dehdashti
- Not yet recruiting
Barrow Neurological Institute
Phoenix, Arizona, 85013
Michael Lawton
- Not yet recruiting
Mayo Clinic
Rochester, Minnesota, 55902
Giuseppe Lanzino
- Not yet recruiting
UCSF
San Francisco, California, 94143
Mitchel S Berger
- Not yet recruiting
Stanford University
Stanford, California, 94305
Gary K Steinberg
Italy8 sites, 8 recruiting
- Not yet recruiting
University of Florence - Careggi
Florence
Alessandro Della Puppa
- Not yet recruiting
University of Genoa
Genoa
Gianluigi Zona
- Not yet recruiting
University of Messina
Messina
Antonino Germano
- Not yet recruiting
Carlo Besta
Milan
Paolo Ferroli
- Not yet recruiting
Padova University
Padova
Domenico D'Avella
- Not yet recruiting
Gemelli University Hospital
Roma
Alessandro Olivi
- Not yet recruiting
Sapienza University
Roma
Antonio Santoro
- Not yet recruiting
University of Verona
Verona
Giampietro Pinna
Germany7 sites, 7 recruiting
- Not yet recruiting
Charité Univesitätsmedizin
Berlin
Peter Vajkoczy
- Not yet recruiting
University of Cologne
Cologne
Roland Goldbrunner
- Not yet recruiting
Dresden Uniklinikum
Dresden
Gabriele Schackert
- Not yet recruiting
Düsseldorf Universitätsmedizin
Düsseldorf
Daniel Hänggi
- Not yet recruiting
Frankfurt University
Frankfurt
Volker Seifert
- Not yet recruiting
Universitätsmedizin Göttingen
Göttingen
Veit Rohde
- Not yet recruiting
Unimedizin Mainz
Mainz
Florian Ringel
Netherlands3 sites, 3 recruiting
- Not yet recruiting
Amsterdam UMC
Amsterdam
W. Peter Vandertop
- Not yet recruiting
Leiden University
Leiden
Wilco C Peul
- Not yet recruiting
UMC Utrecht
Utrecht
Albert van der Zwan
Australia2 sites, 2 recruiting
- Not yet recruiting
Royal Melbourne Hospital
Melbourne
Kate Drummond
- Not yet recruiting
Macquarie University
Sydney
Antonio Di Ieva
Austria2 sites, 2 recruiting
- Not yet recruiting
Innsbruck University
Innsbruck
Claudius Thomé
- Not yet recruiting
Linz Kepler Klinikum
Linz
Andreas Gruber
Switzerland2 sites, 2 recruiting
- Not yet recruiting
Inselspital Bern
Bern
Andreas Raabe
- Recruiting
University Hospital Zurich
Zurich
Victor Staartjes
Giuseppe Esposito
Czechia1 site, 1 recruiting
- Not yet recruiting
Prague University
Prague
Vladimir Benes
Russia1 site, 1 recruiting
- Not yet recruiting
Burdenko Hospital
Moscow
Eliava Shalva
Sweden1 site, 1 recruiting
- Not yet recruiting
Sahlgrenska Hospital
Gothenburg
Asgeir Jakola
About this study
Official title: The Prediction of Adverse Events After Microsurgery for Intracranial Unruptured Aneurysms (PRAEMIUM) Study
Accurate preoperative identification of patients at high risk for adverse outcomes would be clinically advantageous, as it would allow enhanced resource preparation, better surgical decision-making, enhanced patient education and informed consent, and potentially even modification of certain modifiable risk factors. The aim of the Prediction of adverse events after microsurgery for intracranial unruptured aneurysms (PRAEMIUM) study is therefore to develop and externally validate a clinically applicable, robust ML-based prediction tool based on multicenter data from a range of international centers.
Read the detailed description
Introduction Unruptured intracranial aneurysms (UIAs) are incidentally detected at an increasing rate, mostly owing to the rise in availability of non-invasive cranial imaging. Decision-making in UIAs is complex and requires consideration of many risk factors for aneurysm growth and rupture to balance the benefits and risks of treatment versus observation. This is due to: 1) the high morbidity and case fatality inherent to aneurysmal subarachnoid hemorrhage (SAH) 2) the relatively low rupture rate of unruptured aneurysms; 3) the potential morbidity and mortality rate associated with either microsurgical or endovascular treatment.
Some consistent risk factors for rupture have been identified, including involvement of the posterior circulation, larger diameter, higher age, and some specific populations such as Japanese and Finnish patients. Many other risk factors have been suggested based on varying levels of evidence. However, it is difficult to integrate this considerable number of factors into a single risk assessment and to present a clear clinical decision making algorithm to patients. A range of scoring systems have been developed and validated to approximate the risk of rupture (PHASES) and growth (ELAPSS) or to balance the risks and benefits of microsurgical treatment versus follow-up imaging directly (UIATS) by integrating some of these risk factors. Still, these scores are focused on predicting rupture events instead of neurological outcome. In addition, they usually are focused on solely one outcome, instead of providing a wide range of objective predictive analytics that may then improve shared decision-making.
Machine learning (ML) methods have been extraordinarily effective at integrating many clinical patient variables into one holistic risk prediction tailored to each patient. A previous pilot study has been carried out to assess the feasibility of predicting surgical outcomes after surgery for UIAs in a small single-center sample, and it was found that prediction was feasible with good performance metrics, and the most important factors to be included in such models were also identified. A robust, multicenter, externally validated prediction model or predictive score for surgical outcome after microsurgery for UIAs does not yet exist.
Methods Data will be collected by a range of international centers. Overall, the model will be built and publication will be compiled according to the transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD) guidelines.
Each center will collect their data either retrospectively, or from a prospective registry, or from a prospective registry supplemented by retrospectively collected variables. Data from patients operated from January 1st 2010 and onwards will be eligible for inclusion. Data collection should be completed, and deidentified data should be sent to the sponsor institution.
A standardized Excel spreadsheet will be provided by the sponsor. The data will be entered in standardized and anonymized form. This spreadsheet will only contain a study-specific patient number. The data set is anonymized source data that includes clinical data extracted from electronic health records (retrospectively or from a prospective registry of already existing data). The data will be anonymized upon entering them into the PRAEMIUM Excel spreadsheet, after which the patients will be numbered consecutively and there will be no way to trace the data back to individual patients. No identifiable data such as date of birth will be included. Whenever the PRAEMIUM Excel spreadsheet is transferred, it will be encrypted using a password and sent through a secure institutional e-mail server. The password will be sent in a separate e-mail. Some missing data is acceptable, but should be kept to a minimum (i.e. must be < 10%)
Endpoint Definitions Models will be developed for the following three endpoints at discharge: Poor neurological outcome (1), as well as presence of (2) new sensorimotor neurological deficits and (3) any complications (surgical or non-surgical). Neurological outcome was assessed by the modified Rankin scale (mRS), and a favorable neurological outcome was defined as mRS 0, 1, or 2. Complications will be assessed using the modified 2009 Clavien-Dindo grading (CDG), and occurrence of a complication was defined as any deviation from CDG 0.The Clavien-Dindo grading system is a classification of surgical complications: Grad 0 signifying no complication, Grade I identifying complications with any deviation from the normal intra- or postoperative course requiring medical treatment, and so forth. Detailed definitions are provided in the Excel spreadsheet. Surgery-related as well as none-surgery-related complications are counted. In case of multiple complications, only the complication with the highest CDG was counted per patient.
Input Feature Definitions All features are measured preoperatively. Recorded baseline variables will include age, gender, maximum aneurysm diameter, anatomical location (artery), total number of aneurysms per patient, if multiple aneurysms were treated during the index session, calcification of the aneurysm wall or neck, aneurysm morphology (saccular, dissecting, fusiform, or other), involvement of critical perforating or branch vessels, and intraluminal thrombosis.
In addition, the investigators will capture prior SAH, mRS at admission, prior aneurysm treatment, presence of anticoagulation/antiplatelet therapy preoperatively, and hypertension, as well as American Society of Anesthesiologists (ASA) grading, the PHASES, ELAPSS, and UIATS scores including the UIATS "pro-repair" and "pro-conservative treatment" subscores. The unruptured intracranial aneurysm treatment score (UIATS) consists of two subscores: One that represents the strength of recommendation for invasive repair of an unruptured aneurysm, and one that represents the strength of recommendation for conservative management of an unruptured aneurysm. The final overall UIATS score is subsequently calculated as the difference between the two subscores. Also included was the surgical approach: minimally invasive or standard approach, and whether a bypass was performed.
- Conditions
- Aneurysm, Brain
- Being tested
- Microsurgery
- Keywords
- machine learning, unruptured aneurysm
- Medical subject headings
- Intracranial Aneurysm
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MicrosurgeryProcedure or surgery
Microsurgery for unruptured intracranial aneurysm
| Study group | Role | What they receive |
|---|---|---|
| Patients with unruptured brain aneurysms | We will include all adult patients (18 years or older) undergoing microsurgical treatment for UIAs. No specific exclusion criteria will be set. Patients with prior SAH may only be included when surgical treatment occurred at least 4 weeks after ictus. Only patients treated from January 1st 2010 onwards can be included in this study.
No intervention. Receives: Procedure: Microsurgery |
What is being measured
The primary outcome is the main question the study is designed to answer.
modified Rankin Scale
Neurological outcome was assessed by the modified Rankin scale (mRS), and a favorable neurological outcome was defined as mRS 0, 1, or 2. The scale runs from 0 to 5, and higher scores mean a worse outcome.
Measured: Within 24 hours of admission to discharge, assessed up to 30 days
Sensorimotor neurological deficits
Any new sensorimotor neurological deficits after surgery will be captured.
Measured: Within 24 hours of admission to discharge, assessed up to 30 days
Clavien Dindo Complication Grading
Complications will be assessed using the modified 2009 Clavien-Dindo grading (CDG), and occurrence of a complication was defined as any deviation from CDG 0. The CDG runs from 0 to 5, and higher scores mean a worse complication.
Measured: Within 24 hours of admission to discharge, assessed up to 30 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Mar 2021
- Study start20 May 2021
- Primary completion1 Jan 2022 (estimated)
- Study completion1 Oct 2022 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Aneurysm, BrainStudies of the same condition, open and under way.
- More trials run by University of ZurichThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 4,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Zurich
- Sponsor type
- University, hospital or other
- Collaborators
- Macquarie University, Australia, University of Melbourne, Kepler University Hospital, Medical University Innsbruck, General University Hospital, Prague, Universitätsklinikum Köln, Goethe University, University Medical Center Mainz, University of Göttingen, University Hospital Dresden, Charite University, Berlin, Germany, Heinrich-Heine University, Duesseldorf, University of Roma La Sapienza, University of Padova, University of Florence, Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta, University of Messina, Universita di Verona, University of Genua, Italy, Leiden University Medical Center, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), UMC Utrecht, Burdenko Neurosurgery Institute, Sahlgrenska University Hospital, University of Bern, Barrow Neurological Institute, Stanford University, Emory University, University of Wisconsin, Madison, University of California, San Francisco, University of Illinois Chicago, Brigham and Women's Hospital, Mayo Clinic, University of California, Los Angeles, Endeavor Health, Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Responsible party
- Sponsor
- Investigators
- Victor Staartjes, Principal investigator, USZGiuseppe Esposito, Principal investigator, USZ
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04819074
- Sponsor's protocol ID
- PRAEMIUM
- Acronym
- PRAEMIUM
- Status last verified
- Dec 2021
- First submitted
- 18 Mar 2021
- Last updated
- 21 Dec 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Staartjes VE, Adamides AA, Anania P, Baskaya MK, Benes V, Dehdashti AR, Di Ieva A, Ferroli P, Jakola AS, Lanzino G, Lawton MT, Petr O, Petutschnigg T, Pinna G, Podlesek D, Radovanovic I, Rohde V, Stroh-Holly N, Sturiale CL, Wang AC, Regli L, Esposito G; PRAEMIUM investigators. Contemporary adverse event profile of microsurgery for intracranial unruptured aneurysms in high-volume microsurgical centers: the international PRAEMIUM study. Neurosurg Focus. 2025 Dec 1;59(6):E18. doi: 10.3171/2025.9.FOCUS25723.
PubMed 41343785
Study at a glance
From the registry record, last updated by the sponsor on 21 Dec 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Prediction of Adverse Events After Microsurgery for Intracranial Unruptured Aneurysms (PRAEMIUM) Study
- ClinicalTrials.gov ID
- NCT04819074
- Acronym / sponsor ID
- PRAEMIUM / PRAEMIUM
- Conditions
- Aneurysm, Brain
- Keywords
- machine learning, unruptured aneurysm
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 4,000 participants (estimated)
- Lead sponsor
- University of ZurichUniversity, hospital or other
- Collaborators
- Macquarie University, Australia, University of Melbourne, Kepler University Hospital, Medical University Innsbruck, General University Hospital, Prague, Universitätsklinikum Köln, Goethe University, University Medical Center Mainz, University of Göttingen, University Hospital Dresden, Charite University, Berlin, Germany, Heinrich-Heine University, Duesseldorf, University of Roma La Sapienza, University of Padova, University of Florence, Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta, University of Messina, Universita di Verona, University of Genua, Italy, Leiden University Medical Center, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), UMC Utrecht, Burdenko Neurosurgery Institute, Sahlgrenska University Hospital, University of Bern, Barrow Neurological Institute, Stanford University, Emory University, University of Wisconsin, Madison, University of California, San Francisco, University of Illinois Chicago, Brigham and Women's Hospital, Mayo Clinic, University of California, Los Angeles, Endeavor Health, Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Study start
- 20 May 2021 (actual)
- Primary completion
- 1 Jan 2022 (estimated)
- Study completion
- 1 Oct 2022 (estimated)
- First posted
- 26 Mar 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Accurate preoperative identification of patients at high risk for adverse outcomes would be clinically advantageous, as it would allow enhanced resource preparation, better surgical decision-making, enhanced patient education and informed consent, and potentially even modification of certain modifiable risk factors. The aim of the Prediction of adverse events after microsurgery for intracranial unruptured aneurysms (PRAEMIUM) study is therefore to develop and externally validate a clinically applicable, robust ML-based prediction tool based on multicenter data from a range of international centers.
Detailed description
Introduction Unruptured intracranial aneurysms (UIAs) are incidentally detected at an increasing rate, mostly owing to the rise in availability of non-invasive cranial imaging. Decision-making in UIAs is complex and requires consideration of many risk factors for aneurysm growth and rupture to balance the benefits and risks of treatment versus observation. This is due to: 1) the high morbidity and case fatality inherent to aneurysmal subarachnoid hemorrhage (SAH) 2) the relatively low rupture rate of unruptured aneurysms; 3) the potential morbidity and mortality rate associated with either microsurgical or endovascular treatment.
Some consistent risk factors for rupture have been identified, including involvement of the posterior circulation, larger diameter, higher age, and some specific populations such as Japanese and Finnish patients. Many other risk factors have been suggested based on varying levels of evidence. However, it is difficult to integrate this considerable number of factors into a single risk assessment and to present a clear clinical decision making algorithm to patients. A range of scoring systems have been developed and validated to approximate the risk of rupture (PHASES) and growth (ELAPSS) or to balance the risks and benefits of microsurgical treatment versus follow-up imaging directly (UIATS) by integrating some of these risk factors. Still, these scores are focused on predicting rupture events instead of neurological outcome. In addition, they usually are focused on solely one outcome, instead of providing a wide range of objective predictive analytics that may then improve shared decision-making.
Machine learning (ML) methods have been extraordinarily effective at integrating many clinical patient variables into one holistic risk prediction tailored to each patient. A previous pilot study has been carried out to assess the feasibility of predicting surgical outcomes after surgery for UIAs in a small single-center sample, and it was found that prediction was feasible with good performance metrics, and the most important factors to be included in such models were also identified. A robust, multicenter, externally validated prediction model or predictive score for surgical outcome after microsurgery for UIAs does not yet exist.
Methods Data will be collected by a range of international centers. Overall, the model will be built and publication will be compiled according to the transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD) guidelines.
Each center will collect their data either retrospectively, or from a prospective registry, or from a prospective registry supplemented by retrospectively collected variables. Data from patients operated from January 1st 2010 and onwards will be eligible for inclusion. Data collection should be completed, and deidentified data should be sent to the sponsor institution.
A standardized Excel spreadsheet will be provided by the sponsor. The data will be entered in standardized and anonymized form. This spreadsheet will only contain a study-specific patient number. The data set is anonymized source data that includes clinical data extracted from electronic health records (retrospectively or from a prospective registry of already existing data). The data will be anonymized upon entering them into the PRAEMIUM Excel spreadsheet, after which the patients will be numbered consecutively and there will be no way to trace the data back to individual patients. No identifiable data such as date of birth will be included. Whenever the PRAEMIUM Excel spreadsheet is transferred, it will be encrypted using a password and sent through a secure institutional e-mail server. The password will be sent in a separate e-mail. Some missing data is acceptable, but should be kept to a minimum (i.e. must be < 10%)
Endpoint Definitions Models will be developed for the following three endpoints at discharge: Poor neurological outcome (1), as well as presence of (2) new sensorimotor neurological deficits and (3) any complications (surgical or non-surgical). Neurological outcome was assessed by the modified Rankin scale (mRS), and a favorable neurological outcome was defined as mRS 0, 1, or 2. Complications will be assessed using the modified 2009 Clavien-Dindo grading (CDG), and occurrence of a complication was defined as any deviation from CDG 0.The Clavien-Dindo grading system is a classification of surgical complications: Grad 0 signifying no complication, Grade I identifying complications with any deviation from the normal intra- or postoperative course requiring medical treatment, and so forth. Detailed definitions are provided in the Excel spreadsheet. Surgery-related as well as none-surgery-related complications are counted. In case of multiple complications, only the complication with the highest CDG was counted per patient.
Input Feature Definitions All features are measured preoperatively. Recorded baseline variables will include age, gender, maximum aneurysm diameter, anatomical location (artery), total number of aneurysms per patient, if multiple aneurysms were treated during the index session, calcification of the aneurysm wall or neck, aneurysm morphology (saccular, dissecting, fusiform, or other), involvement of critical perforating or branch vessels, and intraluminal thrombosis.
In addition, the investigators will capture prior SAH, mRS at admission, prior aneurysm treatment, presence of anticoagulation/antiplatelet therapy preoperatively, and hypertension, as well as American Society of Anesthesiologists (ASA) grading, the PHASES, ELAPSS, and UIATS scores including the UIATS "pro-repair" and "pro-conservative treatment" subscores. The unruptured intracranial aneurysm treatment score (UIATS) consists of two subscores: One that represents the strength of recommendation for invasive repair of an unruptured aneurysm, and one that represents the strength of recommendation for conservative management of an unruptured aneurysm. The final overall UIATS score is subsequently calculated as the difference between the two subscores. Also included was the surgical approach: minimally invasive or standard approach, and whether a bypass was performed.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patients with unruptured brain aneurysms | – | Procedure: MicrosurgeryWe will include all adult patients (18 years or older) undergoing microsurgical treatment for UIAs. No specific exclusion criteria will be set. Patients with prior SAH may only be included when surgical treatment occurred at least 4 weeks after ictus. Only patients treated from January 1st 2010 onwards can be included in this study. No intervention. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- We will include all adult patients (18 years or older) undergoing microsurgical treatment for UIAs. No specific exclusion criteria will be set. Patients with prior SAH may only be included when surgical treatment occurred at least 4 weeks after ictus. Only patients treated from January 1st 2010 onwards can be included in this study.
Key inclusion criteria (4 listed)
- Adult patients (18 or older)
- Undergone microsurgical treatment for unruptured intracranial aneurysm
- Patients with prior SAH may only be included when surgical treatment occurred at least 4 weeks after ictus.
- Treated from January 1st 2010 onwards
Key exclusion criteria (1 listed)
- No specific exclusion criteria
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MicrosurgeryMicrosurgery for unruptured intracranial aneurysm | Procedure or surgery | Patients with unruptured brain aneurysms |
Primary outcome
modified Rankin Scale
Time frame: Within 24 hours of admission to discharge, assessed up to 30 days
Neurological outcome was assessed by the modified Rankin scale (mRS), and a favorable neurological outcome was defined as mRS 0, 1, or 2. The scale runs from 0 to 5, and higher scores mean a worse outcome.
Sensorimotor neurological deficits
Time frame: Within 24 hours of admission to discharge, assessed up to 30 days
Any new sensorimotor neurological deficits after surgery will be captured.
Clavien Dindo Complication Grading
Time frame: Within 24 hours of admission to discharge, assessed up to 30 days
Complications will be assessed using the modified 2009 Clavien-Dindo grading (CDG), and occurrence of a complication was defined as any deviation from CDG 0. The CDG runs from 0 to 5, and higher scores mean a worse complication.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Dec 2021.
- Derived from this study: PubMed 41343785Staartjes VE, Adamides AA, Anania P, Baskaya MK, Benes V, Dehdashti AR, Di Ieva A, Ferroli P, Jakola AS, Lanzino G, Lawton MT, Petr O, Petutschnigg T, Pinna G, Podlesek D, Radovanovic I, Rohde V, Stroh-Holly N, Sturiale CL, Wang AC, Regli L, Esposito G; PRAEMIUM investigators. Contemporary adverse event profile of microsurgery for intracranial unruptured aneurysms in high-volume microsurgical centers: the international PRAEMIUM study. Neurosurg Focus. 2025 Dec 1;59(6):E18. doi: 10.3171/2025.9.FOCUS25723.
- Individual participant dataSharing planned: No
Related trials for Aneurysm, Brain
Recruiting
Early Motor-Cognitive Integrative Training on Cognitive and Motor Performance in Patients With Aneurysmal Subarachnoid Hemorrhage
Subarachnoid Aneurysm Hemorrhage
RecruitingObservational study
Determining the Clinical Impact and Prevalence of Hemorrhagic Subtypes in Perimesencephalic Subarachnoid Hemorrhage
Subarachnoid Hemorrhage, Spontaneous, Subarachnoid Hemorrhage, Aneurysmal
Not yet recruitingPhase 1/2
Induced Suppression of Platelet Activity in Aneurysmal Subarachnoid Hemorrhage Management-2 (iSPASM-2)
Aneurysmal Subarachnoid Hemorrhage
RecruitingObservational study
A Study of Choydar Flow-Directed Mesh Stent in the Treatment of Unruptured Intracranial Aneurysms
Intracranial Aneurysm
Not yet recruiting
Effect of Bilateral Greater Occipital Nerve Block on Headache After Intracranial Aneurysm Coiling
Intracranial Aneurysm, Postoperative Pain
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Victor Staartjes principal investigator
USZ
Giuseppe Esposito principal investigator
USZ
37 sites in 10 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Aneurysm, Brain, run by University of Zurich at 37 sites in 10 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 21 Dec 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 37 sites in United States, Italy, Germany, Netherlands, Australia and 5 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Victor Staartjes (+41 44 255 2660, praemium@usz.ch), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
modified Rankin Scale (time frame: Within 24 hours of admission to discharge, assessed up to 30 days). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04819074, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Dec 2021.